Literature DB >> 1703242

Influence of age and endocrine factors on the volume of benign prostatic hyperplasia.

A W Partin1, J E Oesterling, J I Epstein, R Horton, P C Walsh.   

Abstract

To determine whether endocrine factors influence the volume of benign prostatic hyperplasia (BPH), 23 hormonal factors were measured in the serum of 64 men ages 42 to 71 years with low volume prostatic cancer and these levels were correlated with the volume of benign hyperplastic tissue in their radical prostatectomy specimens. With age there was a significant increase in the volume of BPH. Also with age there was a significant decrease in the serum levels of free testosterone, androstenedione, dehydroepiandronsterone (DHA), dehydroepiandronsterone sulphate (DHA-S), delta 5-androstenediol, and 17-hydroxypregnenolone, and a significant increase in sex hormone-binding globulin (SHBG), LH, and FSH. When BPH volume and hormone levels were corrected for age, BPH volume correlated positively with free testosterone, estradiol, and estriol. These data indicate that with age patients with larger volumes of BPH have higher serum androgen and estrogen levels suggesting that serum androgen and estrogen levels may be factors in the persistent stimulation of BPH with age. If so, therapeutic attempts at lowering plasma testosterone levels, reducing estrogen levels, or blocking androgenic stimulation through other mechanisms may interfere with the progression of BPH with age. Conversely, the fact that androgen production declines gradually with age may explain the observation that only 20 to 30% of men who live to age 80 require surgical treatment for urinary obstruction from BPH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703242     DOI: 10.1016/s0022-5347(17)38353-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  The comparison of GLUT-4 and nNOS expression in diabetic and non-diabetic patients with BPH/LUTS.

Authors:  Alper Otunctemur; Huseyin Besiroglu; Murat Dursun; Levent Ozcan; Emre Can Polat; Adnan Somay; Nurver Ozbay; Kutan Ozer; Emin Ozbek
Journal:  Int Urol Nephrol       Date:  2015-04-03       Impact factor: 2.370

2.  Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia.

Authors:  M Tsugaya; F K Habib; G D Chisholm; M Ross; K Tozawa; Y Hayashi; K Kohri; S Tanaka
Journal:  Urol Res       Date:  1996

3.  Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life.

Authors:  Joseph John Bianco; Stephen John McPherson; Hong Wang; Gail S Prins; Gail Petuna Risbridger
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 4.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

Review 5.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

Review 6.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

7.  Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer.

Authors:  Harold D Love; S Erin Booton; Braden E Boone; Joan P Breyer; Tatsuki Koyama; Monica P Revelo; Scott B Shappell; Jeffrey R Smith; Simon W Hayward
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

8.  Challenging the Inevitability of Prostate Enlargement: Low Levels of Benign Prostatic Hyperplasia Among Tsimane Forager-Horticulturalists.

Authors:  Benjamin C Trumble; Jonathan Stieglitz; Daniel Eid Rodriguez; Edhitt Cortez Linares; Hillard S Kaplan; Michael D Gurven
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-04-28       Impact factor: 6.053

9.  Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men?

Authors:  John C Mavropoulos; Alan W Partin; Christopher L Amling; Martha K Terris; Christopher J Kane; William J Aronson; Joseph C Presti; Leslie A Mangold; Stephen J Freedland
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

10.  The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: a review.

Authors:  K Stamatiou; M Lardas; E Kostakos; V Koutsonasios; E Michail
Journal:  Adv Urol       Date:  2009-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.